成为科学、商业、经营管理交叉点的两个会议
针对生物医药企业的研究开发 (R&D)、业务分析和决策
在不断变化的当前制药行业的研究开发 (R&D) 形势下，药物开发项目组合管理、组合优先顺序、容量管理、资源预测、风险缓解、战略决策已成为最重要的课题。剑桥健康技术研究所的生物制药策略系列不仅解释了制药和生物技术企业中高层管理人员的决策过程，还提供高层次的讨论、互动式分组会议、人脉建立机会、小规模对话、以及一对一的个别会议。与会者可以获得新工具和组织战略，并将其用于项目规划、项目组合分析和决策优化。同时，能够根据项目组合的优先级进行资源的规划、配置和容量管理。
相关组织
2024年主题演讲嘉宾
Michelle Shogren
CEO & Owner, Innovate in What You Do!
Senior Director of Innovation, Pharma R&D Clinical Operations, Bayer
Mary Lou Panzano
Founder and CEO, Panzano Enterprises LLC
Former Vice President, Internal Communications, Bayer
Helen J. Merianos, PhD
Head, R&D Portfolio Strategy, Sanofi
Michael Myers, PhD
Associate Vice President, LRL, Project Management-Due Diligence, Eli Lilly and Company
Peter Ray
Vice President, Head of, Portfolio Analytics, Novartis
Leslie Lippard
Senior Director, Portfolio, Analytics, Alnylam
2024年Advisory Board
Michael Ferrante
Executive Director, Portfolio Prioritization, Global Regulatory Affairs & Clinical Safety, Merck
Sean Gallagher
Director, Capacity Management and Business Analytics, Janssen
Leslie Lippard
Senior Director, Portfolio Analytics, Alnylam Pharmaceuticals
Michael Myers
Associate Vice President, LRL Project Management - Due Diligence, Eli Lilly & Co.
Joe Stalder
Vice President, Program Management, Zentalis Pharmaceuticals
